The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders

Sayantani B. Sindher; Suzanne Barshow; Jyothi Tirumalasetty; Stefania Arasi; Dan Atkins; Maureen Bauer; Philippe Bégin; Margaret H. Collins; Antoine Deschildre; Alfred D. Doyle; Alessandro Fiocchi; Glenn T. Furuta; Maria Garcia-Lloret; Maurizio Mennini; Marc E. Rothenberg; Jonathan M. Spergel; Julie Wang; Robert A. Wood; Benjamin L. Wright; Torsten Zuberbier; Andrew R. Chin; Andrew Long; Kari C. Nadeau; R. Sharon Chinthrajah

doi:10.1016/j.jaci.2023.01.007

The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders

Sayantani B. Sindher, Suzanne Barshow, Jyothi Tirumalasetty, Stefania Arasi, Dan Atkins, Maureen Bauer, Philippe Bégin, Margaret H. Collins, Antoine Deschildre, Alfred D. Doyle, Alessandro Fiocchi, Glenn T. Furuta, Maria Garcia-Lloret, Maurizio Mennini, Marc E. Rothenberg, Jonathan M. Spergel, Julie Wang, Robert A. Wood, Benjamin L. Wright, Torsten ZuberbierAndrew R. Chin, Andrew Long, Kari C. Nadeau, R. Sharon Chinthrajah

Allergy, Asthma and Clinical Immunology

Research output: Contribution to journal › Review article › peer-review

Abstract

Continuing insight into the molecular mechanisms of atopic disorders has enabled the development of biologics to precisely target these diseases. Food allergy (FA) and eosinophilic gastrointestinal disorders (EGIDs) are driven by similar inflammatory molecular mechanisms and exist along the same atopic disease spectrum. Therefore, many of the same biologics are being investigated to target key drivers of mechanisms shared across the disease states. The enormous potential of biologics for the treatment of FA and EGIDs is highlighted by the significant increases in the number of ongoing clinical trials (more than 30) evaluating their use in these disease states, as well as by the recent US Food and Drug Administration approval of dupilumab for the treatment of eosinophilic esophagitis. Here we discuss past and current research into the use of biologics in FA and EGIDs and their potential role in improving treatment options in the future, with the need to have biologics widely clinically available.

Original language	English (US)
Pages (from-to)	595-606
Number of pages	12
Journal	Journal of Allergy and Clinical Immunology
Volume	151
Issue number	3
DOIs	https://doi.org/10.1016/j.jaci.2023.01.007
State	Published - Mar 2023

Keywords

Food allergy
biologics
eosinophilic colitis
eosinophilic enteritis
eosinophilic esophagitis
eosinophilic gastritis
eosinophilic gastrointestinal disorders
oral immunotherapy

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2023.01.007

Cite this

Sindher, S. B., Barshow, S., Tirumalasetty, J., Arasi, S., Atkins, D., Bauer, M., Bégin, P., Collins, M. H., Deschildre, A., Doyle, A. D., Fiocchi, A., Furuta, G. T., Garcia-Lloret, M., Mennini, M., Rothenberg, M. E., Spergel, J. M., Wang, J., Wood, R. A., Wright, B. L., ... Chinthrajah, R. S. (2023). The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders. Journal of Allergy and Clinical Immunology, 151(3), 595-606. https://doi.org/10.1016/j.jaci.2023.01.007

Sindher, SB, Barshow, S, Tirumalasetty, J, Arasi, S, Atkins, D, Bauer, M, Bégin, P, Collins, MH, Deschildre, A, Doyle, AD, Fiocchi, A, Furuta, GT, Garcia-Lloret, M, Mennini, M, Rothenberg, ME, Spergel, JM, Wang, J, Wood, RA, Wright, BL, Zuberbier, T, Chin, AR, Long, A, Nadeau, KC & Chinthrajah, RS 2023, 'The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders', Journal of Allergy and Clinical Immunology, vol. 151, no. 3, pp. 595-606. https://doi.org/10.1016/j.jaci.2023.01.007

@article{045cc1ca86464d7fb507931cd78a7f28,

title = "The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders",

abstract = "Continuing insight into the molecular mechanisms of atopic disorders has enabled the development of biologics to precisely target these diseases. Food allergy (FA) and eosinophilic gastrointestinal disorders (EGIDs) are driven by similar inflammatory molecular mechanisms and exist along the same atopic disease spectrum. Therefore, many of the same biologics are being investigated to target key drivers of mechanisms shared across the disease states. The enormous potential of biologics for the treatment of FA and EGIDs is highlighted by the significant increases in the number of ongoing clinical trials (more than 30) evaluating their use in these disease states, as well as by the recent US Food and Drug Administration approval of dupilumab for the treatment of eosinophilic esophagitis. Here we discuss past and current research into the use of biologics in FA and EGIDs and their potential role in improving treatment options in the future, with the need to have biologics widely clinically available.",

keywords = "Food allergy, biologics, eosinophilic colitis, eosinophilic enteritis, eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastrointestinal disorders, oral immunotherapy",

author = "Sindher, {Sayantani B.} and Suzanne Barshow and Jyothi Tirumalasetty and Stefania Arasi and Dan Atkins and Maureen Bauer and Philippe B{\'e}gin and Collins, {Margaret H.} and Antoine Deschildre and Doyle, {Alfred D.} and Alessandro Fiocchi and Furuta, {Glenn T.} and Maria Garcia-Lloret and Maurizio Mennini and Rothenberg, {Marc E.} and Spergel, {Jonathan M.} and Julie Wang and Wood, {Robert A.} and Wright, {Benjamin L.} and Torsten Zuberbier and Chin, {Andrew R.} and Andrew Long and Nadeau, {Kari C.} and Chinthrajah, {R. Sharon}",

note = "Funding Information: Supported by National Institutes of Health ( NIH ) (grant U54 AI117804 for the Consortium of Eosinophilic Gastrointestinal Disease Researchers [CEGIR]). CEGIR is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), and is cofunded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases, NCATS, and the Intramural Research Program of the NIH. CEGIR is also supported by patient advocacy groups, including the American Partnership for Eosinophilic Disorders , Campaign Urging Research for Eosinophilic Disease , and Eosinophilic Family Coalition. As a member of the RDCRN , CEGIR is also supported by its Data Management and Coordinating Center (DMCC) (grant U2CTR002818). Funding support for the DMCC is provided by NCATS and the National Institute of Neurological Disorders and Stroke . Additional funding has also been provided by the NIAID (grants 5UM1 AI130839-04 NIAID and 5U19 AI1104209-07 NIAID ). Publisher Copyright: {\textcopyright} 2023 American Academy of Allergy, Asthma & Immunology",

year = "2023",

month = mar,

doi = "10.1016/j.jaci.2023.01.007",

language = "English (US)",

volume = "151",

pages = "595--606",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders

AU - Sindher, Sayantani B.

AU - Barshow, Suzanne

AU - Tirumalasetty, Jyothi

AU - Arasi, Stefania

AU - Atkins, Dan

AU - Bauer, Maureen

AU - Bégin, Philippe

AU - Collins, Margaret H.

AU - Deschildre, Antoine

AU - Doyle, Alfred D.

AU - Fiocchi, Alessandro

AU - Furuta, Glenn T.

AU - Garcia-Lloret, Maria

AU - Mennini, Maurizio

AU - Rothenberg, Marc E.

AU - Spergel, Jonathan M.

AU - Wang, Julie

AU - Wood, Robert A.

AU - Wright, Benjamin L.

AU - Zuberbier, Torsten

AU - Chin, Andrew R.

AU - Long, Andrew

AU - Nadeau, Kari C.

AU - Chinthrajah, R. Sharon

N1 - Funding Information: Supported by National Institutes of Health ( NIH ) (grant U54 AI117804 for the Consortium of Eosinophilic Gastrointestinal Disease Researchers [CEGIR]). CEGIR is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), and is cofunded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases, NCATS, and the Intramural Research Program of the NIH. CEGIR is also supported by patient advocacy groups, including the American Partnership for Eosinophilic Disorders , Campaign Urging Research for Eosinophilic Disease , and Eosinophilic Family Coalition. As a member of the RDCRN , CEGIR is also supported by its Data Management and Coordinating Center (DMCC) (grant U2CTR002818). Funding support for the DMCC is provided by NCATS and the National Institute of Neurological Disorders and Stroke . Additional funding has also been provided by the NIAID (grants 5UM1 AI130839-04 NIAID and 5U19 AI1104209-07 NIAID ). Publisher Copyright: © 2023 American Academy of Allergy, Asthma & Immunology

PY - 2023/3

Y1 - 2023/3

N2 - Continuing insight into the molecular mechanisms of atopic disorders has enabled the development of biologics to precisely target these diseases. Food allergy (FA) and eosinophilic gastrointestinal disorders (EGIDs) are driven by similar inflammatory molecular mechanisms and exist along the same atopic disease spectrum. Therefore, many of the same biologics are being investigated to target key drivers of mechanisms shared across the disease states. The enormous potential of biologics for the treatment of FA and EGIDs is highlighted by the significant increases in the number of ongoing clinical trials (more than 30) evaluating their use in these disease states, as well as by the recent US Food and Drug Administration approval of dupilumab for the treatment of eosinophilic esophagitis. Here we discuss past and current research into the use of biologics in FA and EGIDs and their potential role in improving treatment options in the future, with the need to have biologics widely clinically available.

AB - Continuing insight into the molecular mechanisms of atopic disorders has enabled the development of biologics to precisely target these diseases. Food allergy (FA) and eosinophilic gastrointestinal disorders (EGIDs) are driven by similar inflammatory molecular mechanisms and exist along the same atopic disease spectrum. Therefore, many of the same biologics are being investigated to target key drivers of mechanisms shared across the disease states. The enormous potential of biologics for the treatment of FA and EGIDs is highlighted by the significant increases in the number of ongoing clinical trials (more than 30) evaluating their use in these disease states, as well as by the recent US Food and Drug Administration approval of dupilumab for the treatment of eosinophilic esophagitis. Here we discuss past and current research into the use of biologics in FA and EGIDs and their potential role in improving treatment options in the future, with the need to have biologics widely clinically available.

KW - Food allergy

KW - biologics

KW - eosinophilic colitis

KW - eosinophilic enteritis

KW - eosinophilic esophagitis

KW - eosinophilic gastritis

KW - eosinophilic gastrointestinal disorders

KW - oral immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85149063640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149063640&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2023.01.007

DO - 10.1016/j.jaci.2023.01.007

M3 - Review article

C2 - 36872039

AN - SCOPUS:85149063640

SN - 0091-6749

VL - 151

SP - 595

EP - 606

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 3

ER -

The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this